{"title":"Glymphatic flow reduced in Huntington disease","authors":"Ian Fyfe","doi":"10.1038/s41582-025-01103-9","DOIUrl":"https://doi.org/10.1038/s41582-025-01103-9","url":null,"abstract":"Measures of glymphatic function could serve as markers of Huntington disease and its progression, new research has shown.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"3 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"AI aces diagnosis of chronic ataxias","authors":"Ian Fyfe","doi":"10.1038/s41582-025-01102-w","DOIUrl":"https://doi.org/10.1038/s41582-025-01102-w","url":null,"abstract":"A bespoke virtual assistant based on artificial intelligence has outperformed neurologists in the diagnosis of chronic ataxias in a recent study.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"4 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"SEQUINS - a new initiative to address disparities in neurology.","authors":"Heather Wood","doi":"10.1038/s41582-025-01092-9","DOIUrl":"https://doi.org/10.1038/s41582-025-01092-9","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"74 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Menopause, memory and molecular pathways: growing insights into Alzheimer disease risk in women","authors":"Erin E. Sundermann","doi":"10.1038/s41582-025-01093-8","DOIUrl":"https://doi.org/10.1038/s41582-025-01093-8","url":null,"abstract":"Growing evidence links menopause to the risk of Alzheimer disease (AD) in women, but the effect of menopause hormone therapy (MHT) on this risk remain unclear. Two new studies illuminate how menopause and MHT influence synaptic health and tau pathology, offering new insights into sex-specific mechanisms and MHT timing considerations in AD risk.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"119 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143933469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis","authors":"Lisa Kiani","doi":"10.1038/s41582-025-01099-2","DOIUrl":"https://doi.org/10.1038/s41582-025-01099-2","url":null,"abstract":"A population cohort study has shown that Epstein–Barr virus interacts with genetics to increase the risk of multiple sclerosis.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"123 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143939947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dementia with Lewy bodies and Parkinson disease dementia — the same or different and is it important?","authors":"YuHong Fu, Glenda M. Halliday","doi":"10.1038/s41582-025-01090-x","DOIUrl":"https://doi.org/10.1038/s41582-025-01090-x","url":null,"abstract":"<p>Biological definitions of neurological diseases are now becoming a reality, although still in the research phase. This development will recategorize neurological diseases, providing objective diagnostics and the promise of therapeutics that target biological mechanisms — similar to the strategy that has proven successful in tumours and other conditions. In this Perspective article, we discuss this development for dementias with dominant Lewy pathology, as the availability of biological assays for this pathology has sparked new interest in a single disease diagnosis for all individuals positive for α-synuclein. On the basis of current evidence, we argue that an α-synuclein assay alone is unlikely to be a specific criterion for a spectrum of clinical syndromes with Lewy pathology or a definitive diagnostic marker for Lewy body dementia. We advocate that one biological assay will not reflect the complex spatiotemporal features of brain pathology. Diverse sequential mechanisms underpin the highly heterogeneous phenotypes and clinicopathological processes of Lewy body dementias. Disease modification, if possible, will be most effective when it targets the early underlying mechanisms, especially those leading to aggressive phenotypes.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"44 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143933459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mind over microplastics — what we still don’t know","authors":"Michael Aschner","doi":"10.1038/s41582-025-01097-4","DOIUrl":"https://doi.org/10.1038/s41582-025-01097-4","url":null,"abstract":"Microplastics have been observed in human brain tissue for the first time, and higher levels were associated with dementia. However, important questions remain about the mechanisms of microplastic accumulation and clearance, the influence of environmental factors such as geographical location, and whether the association with dementia reflects cause or effect.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"14 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nir Giladi (1955–2024)","authors":"Bastiaan R. Bloem","doi":"10.1038/s41582-025-01095-6","DOIUrl":"https://doi.org/10.1038/s41582-025-01095-6","url":null,"abstract":"<p>Nir Giladi was truly a man on a mission. His rich career was dedicated to fulfilling a beautiful dream: finding a treatment that would slow or stop the progression of Parkinson disease (PD) and ultimately finding a cure. That he was not given enough time to realize these breakthroughs is incredibly sad, yet his legacy is enormous.</p><p>Nir was also among the first to understand that walking and standing involve an important degree of cognitive control<sup>3</sup>, leading him to organize several successful international congresses that focused specifically on the bidirectional interaction between gait and cognitive function. In addition, realizing that conventional medical management is often insufficient to alleviate the disability caused by PD, Nir was a leading figure in the development of multidisciplinary care for people with PD. For him, this concept did not just involve multiple professional disciplines delivering optimal care for patients — he insisted on working closely with affected individuals. Indeed, patient-centeredness was core to his approach, and was palpable throughout his centre of excellence in Tel Aviv.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"101 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143920121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Autoimmune encephalitis-associated epilepsy","authors":"Claude Steriade, Jan Bauer, Christian G. Bien","doi":"10.1038/s41582-025-01089-4","DOIUrl":"https://doi.org/10.1038/s41582-025-01089-4","url":null,"abstract":"<p>Autoimmune encephalitis (AE), defined by clinical criteria and its frequent association with neural autoantibodies, often manifests with seizures, which usually stop with immunotherapy. However, a subset of encephalitic conditions present with recurrent seizures that are resistant to immunotherapy. Three primary neurological constellations that fall within this subset are discussed in this Perspective: temporal lobe epilepsy with antibodies against glutamic acid decarboxylase, epilepsy in the context of high-risk paraneoplastic antibodies, and epilepsy following adequately treated surface antibody-mediated AE. These entities all share a common mechanism of structural injury and potentially epileptogenic focal neural loss, often induced by cytotoxic T cells. Recently, we have proposed conceptualizing these conditions under the term autoimmune encephalitis-associated epilepsy (AEAE). Here, we discuss the new concept of AEAE as an emerging field of study. We consider the clinical characteristics of patients who should be investigated for AEAE and highlight the need for judicious use of traditional epilepsy therapeutics alongside immunotherapeutic considerations that are of uncertain and incomplete efficacy for this group of disorders. Last, we discuss future efforts needed to diagnose individuals before structural epileptogenesis has superseded inflammation and to develop improved therapeutics that target the specific immunological or functional disturbances in this entity.</p>","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"134 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143901402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Implications of AD plasma and PET biomarker discordance","authors":"Charlotte E. Teunissen, Lisa Vermunt","doi":"10.1038/s41582-025-01091-w","DOIUrl":"https://doi.org/10.1038/s41582-025-01091-w","url":null,"abstract":"Plasma biomarker tests for Alzheimer disease are becoming increasingly reliable, which enables implementation in clinical settings in which cerebrospinal fluid analysis and PET scans are unavailable. However, a new study shows that some patients have discordant plasma and PET biomarker results. Clinicians need clear guidance to identify and manage patients who do not fit into standard clinical or biological categories.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"95 1","pages":""},"PeriodicalIF":38.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}